Teva Pharmaceuticals USA, a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., is making a full-court press on getting the word out on the need for follow-on biologics. In its “Year of Affordable Healthcare” campaign, Teva is putting put together videos to argue for generics, just as the White House is making its position known on the need for biogenerics (read: need for lower costs).
The program commemorates the 25th anniversary of the Waxman-Hatch Act which created the modern generic drugs industry and features videos that ask the “man on the street” in Washington, D.C. what they think about healthcare in the U.S. It wouldn’t take the Amazing Kreskin to guess that people want lower healthcare costs. It’s a thorny issue with some biotech therapies costing as much as $500,000 annually.
See more here.
Related posts:
- BIO News Conference: Biotech Will Lead Healthcare and Energy Reform Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood held...
- Court Dismisses Tafas Suit Against Rules; Leaves Lower Court Ruling Intact In the the Tafas v. Kappos lawsuit, Under Secretary of...
- Biotech: It’s Not 1984 Deloitte has released a study, Avoiding no man’s land: Potential...
- Indian Biogenerics on an Upswing India’s pharmaceutical industry caters to about 30% of the world’s...
Related posts brought to you by Yet Another Related Posts Plugin.
